Thrombolytic therapy with urokinase for pulmonary embolism in patients with stable haemodynamics

Yanzhou Zhang, Tongwen Sun, Ben He, Lexin Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)
7 Downloads (Pure)

Abstract

Background. The use of thrombolytic agents in the treatment of haemodynamically stable patients with pulmonary hypertension remains uncertain.Patients and Methods. Urokinase (20,000 IU /kg) was intravenously administered to 36 patients who had pulmonary embolism and a normal blood pressure. This was followed by subcutaneous injection of a low-molecular-weight heparin for a week.Results. Improvement in clinical symptoms and reduction in pulmonary pressure was observed in 28 (77.8%) patients within the first week of the thrombolytic therapy. The improvement rate in patients with embolic symptoms of less than 14 days, and in those who had symptoms between 14 and 30 days before the thrombolytic therapy was 86% and 50%, respectively (p<0.01). Non-life threatening bleeding complications were observed in 10 (22.2%) patients.Conclusions. Thrombolytic therapy with urokinase followed by low-molecular-weight heparin is an effective therapeutic strategy for patients with pulmonary embolism and stable haemodynamics. However, the long-term benefits of this strategy remains to be seen.
Original languageEnglish
Pages (from-to)20-23
Number of pages4
JournalMedical Science Monitor
Volume13
Issue number1
Publication statusPublished - 2007

Fingerprint Dive into the research topics of 'Thrombolytic therapy with urokinase for pulmonary embolism in patients with stable haemodynamics'. Together they form a unique fingerprint.

  • Cite this